The University of Chicago Header Logo

Connection

Louis Philipson to Hypoglycemic Agents

Back to Details
This is a "connection" page, showing publications Louis Philipson has written about Hypoglycemic Agents.
Louis Philipson
Connection Strength
1.179
Hypoglycemic Agents
  1. Approach to the Patient with MODY-Monogenic Diabetes. J Clin Endocrinol Metab. 2021 01 01; 106(1):237-250.
    View in: PubMed
    Score: 0.153
  2. Harnessing heterogeneity in type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 02; 16(2):79-80.
    View in: PubMed
    Score: 0.144
  3. External Validation of the Newly Developed BETA-2 Scoring System for Pancreatic Islet Graft Function Assessment. Transplant Proc. 2017 Dec; 49(10):2340-2346.
    View in: PubMed
    Score: 0.124
  4. Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes. Diabetologia. 2015 Jul; 58(7):1430-5.
    View in: PubMed
    Score: 0.103
  5. Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons. J Clin Endocrinol Metab. 2014 Dec; 99(12):E2709-14.
    View in: PubMed
    Score: 0.101
  6. Calcium-activated and voltage-gated potassium channels of the pancreatic islet impart distinct and complementary roles during secretagogue induced electrical responses. J Physiol. 2010 Sep 15; 588(Pt 18):3525-37.
    View in: PubMed
    Score: 0.074
  7. Neonatal diabetes mellitus: a model for personalized medicine. Trends Endocrinol Metab. 2010 Aug; 21(8):464-72.
    View in: PubMed
    Score: 0.073
  8. Update in neonatal diabetes. Curr Opin Endocrinol Diabetes Obes. 2010 Feb; 17(1):13-9.
    View in: PubMed
    Score: 0.072
  9. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Ann Intern Med. 2023 04; 176(4):eL230007.
    View in: PubMed
    Score: 0.045
  10. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med. 2022 10; 175(10):1392-1400.
    View in: PubMed
    Score: 0.043
  11. Benefit of Continuous Glucose Monitoring in Reducing Hypoglycemia Is Sustained Through 12 Months of Use Among Older Adults with Type 1 Diabetes. Diabetes Technol Ther. 2022 06; 24(6):424-434.
    View in: PubMed
    Score: 0.042
  12. The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis. J Gen Intern Med. 2022 02; 37(2):415-438.
    View in: PubMed
    Score: 0.040
  13. Exenatide extended release in patients with type 1 diabetes with and without residual insulin production. Diabetes Obes Metab. 2020 11; 22(11):2045-2054.
    View in: PubMed
    Score: 0.037
  14. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2020 06 16; 323(23):2397-2406.
    View in: PubMed
    Score: 0.037
  15. The role of ß cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab. 2014 Jun 03; 19(6):1050-7.
    View in: PubMed
    Score: 0.024
  16. Lean versus obese diabetes mellitus patients in the United States minority population. J Diabetes Complications. 2014 Jul-Aug; 28(4):500-5.
    View in: PubMed
    Score: 0.023
  17. ß-Cell-specific protein kinase A activation enhances the efficiency of glucose control by increasing acute-phase insulin secretion. Diabetes. 2013 May; 62(5):1527-36.
    View in: PubMed
    Score: 0.022
  18. Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment. Curr Diab Rep. 2011 Dec; 11(6):519-32.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.